ERBB3 D297Y

CI-VAR-00000470Explore in graph →CIViC 3495

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Esophageal Squamous Cell Carcinoma1
ERBB3 D297Y	Afatinib + Cetuximab + ErlotinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID9675 In an in vitro study, an esophageal squamous cell carcinoma (ESCC) cell line KYSE150 expressing ERBB3 (HER3) D297Y mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib trea… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.